Preferential Selection of Low-Frequency, Lipopolysaccharide-Modified, Colistin-Resistant Mutants with a Combination of Antimicrobials in Acinetobacter baumannii.


Journal

Microbiology spectrum
ISSN: 2165-0497
Titre abrégé: Microbiol Spectr
Pays: United States
ID NLM: 101634614

Informations de publication

Date de publication:
26 10 2022
Historique:
pubmed: 30 9 2022
medline: 29 10 2022
entrez: 29 9 2022
Statut: ppublish

Résumé

Colistin, which targets lipopolysaccharide (LPS), is used as a last-resort drug against severe infections caused by drug-resistant Acinetobacter baumannii. However, A. baumannii possesses two colistin-resistance mechanisms. LPS modification caused by mutations in

Identifiants

pubmed: 36173297
doi: 10.1128/spectrum.01928-22
pmc: PMC9602988
doi:

Substances chimiques

Colistin Z67X93HJG1
Lipopolysaccharides 0
Meropenem FV9J3JU8B1
Carbapenems 0
Anti-Bacterial Agents 0
Ciprofloxacin 5E8K9I0O4U
Disinfectants 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0192822

Références

Clin Infect Dis. 2006 Mar 1;42(5):692-9
pubmed: 16447117
Clin Infect Dis. 2019 Aug 16;69(5):769-776
pubmed: 30462182
Can J Infect Dis Med Microbiol. 2017;2017:1839190
pubmed: 29181039
Lancet Infect Dis. 2018 Apr;18(4):391-400
pubmed: 29456043
Antimicrob Agents Chemother. 2011 Jul;55(7):3370-9
pubmed: 21576434
Front Microbiol. 2014 Nov 26;5:643
pubmed: 25505462
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Antimicrob Agents Chemother. 2014 May;58(5):2972-5
pubmed: 24566189
Microb Drug Resist. 2020 May;26(5):429-433
pubmed: 31657659
Microb Genom. 2019 Oct;5(10):
pubmed: 31599224
J Antimicrob Chemother. 2010 Feb;65(2):233-8
pubmed: 19996144
mBio. 2019 Jul 16;10(4):
pubmed: 31311879
Diagn Microbiol Infect Dis. 2009 May;64(1):43-51
pubmed: 19362258
Antibiotics (Basel). 2020 Mar 12;9(3):
pubmed: 32178356
Front Med (Lausanne). 2021 Aug 12;8:677720
pubmed: 34476235
Front Cell Infect Microbiol. 2017 Mar 13;7:55
pubmed: 28348979
Infection. 2020 Dec;48(6):835-851
pubmed: 32875545
Antimicrob Agents Chemother. 2011 Aug;55(8):3743-51
pubmed: 21646482
Front Cell Infect Microbiol. 2021 Feb 26;11:633817
pubmed: 33718283
Virulence. 2018 Dec 31;9(1):930-942
pubmed: 29638177
Clin Microbiol Rev. 2008 Jul;21(3):538-82
pubmed: 18625687
J Infect Dis. 2013 Oct 1;208(7):1142-51
pubmed: 23812239
Antimicrob Agents Chemother. 2008 Jan;52(1):333-6
pubmed: 17967915
Emerg Microbes Infect. 2020 Dec;9(1):868-885
pubmed: 32284036
Int J Antimicrob Agents. 2017 May;49(5):526-535
pubmed: 28163137
J Clin Microbiol. 2012 Nov;50(11):3609-13
pubmed: 22933604
Eur J Clin Microbiol Infect Dis. 2018 Jun;37(6):1009-1019
pubmed: 29524060
Front Microbiol. 2016 Nov 01;7:1715
pubmed: 27847502
Eur J Clin Microbiol Infect Dis. 2018 Mar;37(3):443-454
pubmed: 29353377
Microb Pathog. 2020 Feb;139:103887
pubmed: 31765766
Antimicrob Agents Chemother. 2011 Jun;55(6):3022-4
pubmed: 21402838
PLoS Comput Biol. 2017 Jun 8;13(6):e1005595
pubmed: 28594827
Pathog Dis. 2014 Aug;71(3):292-301
pubmed: 24376225
mBio. 2021 Dec 21;12(6):e0309921
pubmed: 34844428
Antimicrob Agents Chemother. 2010 Dec;54(12):4971-7
pubmed: 20855724
Sci Rep. 2017 Oct 27;7(1):14216
pubmed: 29079752
J Chemother. 2021 Feb;33(1):1-11
pubmed: 32677578
J Antimicrob Chemother. 2018 Nov 1;73(11):2952-2959
pubmed: 30124845
J Antimicrob Chemother. 2010 Dec;65(12):2598-601
pubmed: 20861141
Antimicrob Agents Chemother. 2007 Oct;51(10):3471-84
pubmed: 17646423
Antimicrob Agents Chemother. 2019 Feb 26;63(3):
pubmed: 30617096
J Antimicrob Chemother. 2012 Jul;67(7):1607-15
pubmed: 22441575
Nat Rev Microbiol. 2018 Feb;16(2):91-102
pubmed: 29249812
Nucleic Acids Res. 2018 Jul 6;46(12):6152-6165
pubmed: 29878158
J Hosp Infect. 2020 Nov;106(3):447-453
pubmed: 32927013
Front Microbiol. 2020 Apr 17;11:573
pubmed: 32373082
J Antimicrob Chemother. 2020 Feb 1;75(2):271-282
pubmed: 31586417
Antimicrob Agents Chemother. 2018 Dec 21;63(1):
pubmed: 30323035
Antibiotics (Basel). 2021 Nov 03;10(11):
pubmed: 34827282
Front Cell Infect Microbiol. 2017 May 24;7:209
pubmed: 28596943
Clin Microbiol Infect. 2019 Sep;25(9):1156.e1-1156.e7
pubmed: 30790686
Clin Infect Dis. 2015 May 1;60(9):1295-303
pubmed: 25632010
Infect Immun. 2005 Nov;73(11):7569-77
pubmed: 16239560
BMC Infect Dis. 2015 Dec 09;15:559
pubmed: 26653099
Nature. 1998 Apr 2;392(6675):449-50
pubmed: 9548250
Infection. 2022 Jun;50(3):569-581
pubmed: 34982411
Mol Microbiol. 2018 Jan;107(1):47-56
pubmed: 29114953
J Antimicrob Chemother. 2015 Nov;70(11):2981-6
pubmed: 26311838
Antibiotics (Basel). 2021 Oct 16;10(10):
pubmed: 34680840
Science. 1996 Nov 8;274(5289):980-2
pubmed: 8875939
Bioinformatics. 2014 Jul 15;30(14):2068-9
pubmed: 24642063
Antibiotics (Basel). 2021 Jul 20;10(7):
pubmed: 34356801
Curr Med Res Opin. 2015 Apr;31(4):707-21
pubmed: 25697677
BMC Res Notes. 2021 Mar 4;14(1):83
pubmed: 33663564
Front Microbiol. 2018 Feb 12;9:153
pubmed: 29483899
Int J Antimicrob Agents. 2020 Mar;55(3):105862
pubmed: 31837449
Nature. 1987 Sep 10-16;329(6135):162-4
pubmed: 3041230

Auteurs

Go Kamoshida (G)

Department of Microbiology and Infection Control Sciences, Kyoto Pharmaceutical Universitygrid.411212.5, Kyoto, Japan.

Noriteru Yamada (N)

Department of Microbiology and Infection Control Sciences, Kyoto Pharmaceutical Universitygrid.411212.5, Kyoto, Japan.

Tomoka Nakamura (T)

Department of Microbiology and Infection Control Sciences, Kyoto Pharmaceutical Universitygrid.411212.5, Kyoto, Japan.

Daiki Yamaguchi (D)

Department of Microbiology and Infection Control Sciences, Kyoto Pharmaceutical Universitygrid.411212.5, Kyoto, Japan.

Daichi Kai (D)

Department of Microbiology and Infection Control Sciences, Kyoto Pharmaceutical Universitygrid.411212.5, Kyoto, Japan.

Maho Yamashita (M)

Department of Microbiology and Infection Control Sciences, Kyoto Pharmaceutical Universitygrid.411212.5, Kyoto, Japan.

Chiaki Hayashi (C)

Department of Microbiology and Infection Control Sciences, Kyoto Pharmaceutical Universitygrid.411212.5, Kyoto, Japan.

Nana Kanda (N)

Department of Microbiology and Infection Control Sciences, Kyoto Pharmaceutical Universitygrid.411212.5, Kyoto, Japan.

Moe Sakaguchi (M)

Department of Microbiology and Infection Control Sciences, Kyoto Pharmaceutical Universitygrid.411212.5, Kyoto, Japan.

Hitoshi Morimoto (H)

Department of Microbiology and Infection Control Sciences, Kyoto Pharmaceutical Universitygrid.411212.5, Kyoto, Japan.

Teppei Sawada (T)

Department of Microbiology and Infection Control Sciences, Kyoto Pharmaceutical Universitygrid.411212.5, Kyoto, Japan.

Tomoko Okada (T)

Department of Microbiology and Infection Control Sciences, Kyoto Pharmaceutical Universitygrid.411212.5, Kyoto, Japan.

Yuki Kaya (Y)

Department of Microbiology and Infection Control Sciences, Kyoto Pharmaceutical Universitygrid.411212.5, Kyoto, Japan.

Norihiko Takemoto (N)

Pathogenic Microbe Laboratory, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan.

Kinnosuke Yahiro (K)

Department of Microbiology and Infection Control Sciences, Kyoto Pharmaceutical Universitygrid.411212.5, Kyoto, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH